Induction of Durable Remission in OID

Post here with questions about other autoimmune diseases or conditions.

Moderators: Mike Bartolatz, kwork

Post Reply
Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Induction of Durable Remission in OID

Post by Mike Bartolatz » Wed May 06, 2009 11:52 am

1: Eur J Ophthalmol. 2009 Jan-Feb;19(1):118-23.Links
Induction of durable remission in ocular inflammatory diseases.Cervantes-Castaneda RA, Bhat P, Fortuna E, Acevedo S, Foster CS.
Massachusetts Eye Research and Surgery Institution, Cambridge, MA - USA.

PURPOSE. To describe a paradigm of care for patients with ocular inflammatory diseases aimed at induction of durable remission. METHODS. Retrospective cohort study. The records of 399 patients with ocular inflammatory diseases treated with systemic immunomodulatory therapy (IMT) at the Massachusetts Eye Research and Surgery Institution were reviewed. Durable remission was defined as control of inflammation in the absence of systemic IMT for at least 1 year. Fifty patients met the inclusion criteria. RESULTS. Mean age was 46+/-22.5 years (range 18-88). All the patients had corticosteroid therapy and failed this therapy before having IMT. Fifty-two percent of the patients had used methotrexate alone or in combination with other medications. Thirty percent of the patients required at least 2 years of therapy with systemic IMT to obtain durable remission, while 44% required 2 to 5 years of therapy to achieve the same. Twenty percent continued to stay in remission, off immunomodulatory drugs, between 2 and 5 years and 18% were in remission for more than 5 years after therapy discontinuation. CONCLUSIONS. IMT can be sight saving in patients. It can be tapered and discontinued successfully without the return of ocular inflammation. Durable drug-free remission is an achievable goal, and should be pursued by ocular inflammatory disease specialists.

PMID: 19123158 [PubMed - in process]

Related articles
Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005 Jun; 112(6):1066-71.
[Ophthalmology. 2005]
Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol. 2009 May; 247(5):687-92. Epub 2009 Feb 6.
[Graefes Arch Clin Exp Ophthalmol. 2009]
Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology. 2008 Dec; 115(12):2146-2152.e1. Epub 2008 Oct 18.
[Ophthalmology. 2008]
ReviewMethotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005 Jan 25; (1):CD003459. Epub 2005 Jan 25.
[Cochrane Database Syst Rev. 2005]
ReviewMethotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2003; (1):CD003459.
[Cochrane Database Syst Rev. 2003]
» See reviews... | » See all...
Patient Drug Information
Methotrexate (Rheumatrex® , Trexall® ) Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physica...
Source: AHFS Consumer Medication Information
Recent Activity Clear Turn Off Turn On
Induction of durable remission in ocular inflammatory diseases.Induction of durable remission in ocular inflammatory diseases.Biologic response modifier therapy for psoriatic ocular inflammatory disease.Biologic response modifier therapy for psoriatic ocular inflammatory disease.Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on
Mike Bartolatz
Moderator

Post Reply